Protective effects of edaravone on diffuse brain injury in rats

doi:10.5847/wjem.j.1920-8642.2011.03.012

Abstract

Abstract:

BACKGROUND: Edaravone can alleviate brain injury and improve neurological functions and symptoms. This study aimed to investigate the effect of edaravone on the p38Mitogen-activated protein kinases/Caspase-3 (p38MAPK /Caspase-3) pathway after diffuse brain injury (DBI) in rats.
METHODS: DBI models were established according to the description of Marmarou's method. A total of 250 rats were divided (random number) into four groups: control group (CG, n=45), model group (MG, n=77), low-dose edaravone group (n=67, dosage 5 mg/kg) and high-dose edaravone group (n=61, dosage 10 mg/kg). After 1, 6, 24, 48, and 72 hours after injury, brain tissues were collected. The changes of neuron morphous in the hippocampal region were observed through Nissl staining. The expression levels of phosphorylated p38MAPK and caspase-3 were detected by immunohistochemistry and Western blotting respectively. Learning and memory function were tested with Morris water maze from the 3rd to 7th day after injury.
RESULTS: Some neurons had histopathologic changes of necrosis and apoptosis in the model group compared with the control group. The phosphorylated p38MAPK expressions increased at 1, 6, 4, and 48 hours (P<0.05), but no significant difference was observed at 72 hours (0.54±0.19 vs. 0.40±0.14, P>0.05). Caspase-3 expressions increased at 6, 24, 48, and 72 hours respectively (P<0.05), but there was no significant difference at 1 hour (0.59±0.29 vs. 0.40±0.17, P>0.05). From the 3rd to 6th day during the Morris water maze test, the latency to find the platform was significantly prolonged (P<0.05) and times of rats crossing the platform was decreased on the 7th day (2.28±1.18 vs. 8.20±1.52, P<0.05). The phosphorylated p38MAPK expressions decreased at 6, 24 and 48 hours respectively in the low dose edaravone group compared with the model group (P<0.05), whereas no significant difference was seen at 1 hour (1.66±0.80 vs. 1.85±0.86, P>0.05). Caspase-3 expression decreased at 6, 24, 48, and 72 hours (P<0.05). The latency to find the platform was significantly shortened (P<0.05), and times of rats crossing the platform increased (4.17±1.15 vs. 2.28±1.18, P<0.05). The above mentioned parameters changed more significantly in the high-dose edaravone group than in the low-dose edaravone group.
CONCLUSION: Edaravone can alleviate brain tissue damage after DBI, inhibit p38MAP signal activation after early injury, reduce the expression of caspase-3, and promote the recovery of neurological function in the late period.

Key words: Diffuse brain injury, Mitogen-activated protein kinases, Caspase-3, Learning-memory, Edaravone

Jian-min Li, Pan Zhang, Ya-ning Zhao, Chang-xiang Chen, Shu-xing Li. Protective effects of edaravone on diffuse brain injury in rats[J]. World Journal of Emergency Medicine, 2011, 2(3): 222-227.

Figures/Tables 6

Figure 1.

Table 1

Figure 2.

Table 2

Figure 3.

Table 3

References 19

1	Zheng GY, Chen XC, Du J, Liu CY, Fang F, Zhang J, et al. Inhibitory action of propyl gallate on the activation of SAPK/JNK a p38MAPK induced by cerebral ischemia-reperfusion in rats. Yao Xue Xue Bao 2006; 41:548-554. pmid: 16927831
2	Mayor F Jr, Jurado-Pueyo M, Campos PM, Murga C. Interfering with MAP kinase docking interactions: implications and perspective for the p38 route. Cell Cycle 2007; 6:528-533. pmid: 17351337
3	Gao Y, Ding XS, Xu S, Wang W, Zuo QL, Kuai F. Neuroprotective effects of edaravone on early brain injury in rats after subarachnoid hemorrhage. Chin Med J (Engl) 2009; 122:1935-1940.
4	Imai K, Mori T, Izumoto H, Takabatake N, Kunieda T, Watanabe M. Hyperbaric oxygen combined with intravenous edaravone for treatment of acute embolic stroke: a pilot clinical trial. Neurol Med Chir (Tokyo). 2006; 46:373-378.
5	Gao Y, Ding XS, Xu S, Wang W, Zuo QL, Kuai F. Neuroprotective effects of edaravone on early brain injury in rats after subarachnoid hemorrhage. Chin Med J (Engl) 2009; 122:1935-1940.
6	Marmarou A, Foda MA, van den Brink W, Campbell J, Kita H, Demetriadou K. A new model of diffuse brain injury in rats. Part I: Pathophysiology and biomechanics. J Neurosurg 1994; 80:291-300. doi: 10.3171/jns.1994.80.2.0291 pmid: 8283269
7	Smith DH, Okiyama K, Thomas MJ, Claussen B, McIntosh TK. Evaluation of memory dysfunction following experimental brain injury using the Morris water maze. J Neurotrauma 1991; 8:259-269.
8	Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 2003; 15:222-229. pmid: 12715790
9	Watanabe T, Yuki S, Egawa M, Nishi H: Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther 1994; 268:1597-1604. pmid: 8138971
10	Nakamoto N, Tada S, Kameyama K, Kitamura K, Kurita S, Saito Y, et al. A free radical scavenger, edaravone, attenuates steatosis and cell death via reducing inflammatory cytokine production in rat acute liver injury. Free Radic Res 2003; 37:849-859. doi: 10.1080/1071576031000136586 pmid: 14567445
11	Lawrence MC, Jivan A, Shao C, Duan L, Goad D, Zaganjor E, et al. The roles of MAPKs in disease. Cell Res 2008; 18:436-442. pmid: 18347614
12	Chaparro-Huerta V, Rivera-Cervantes MC, Flores-Soto ME, Gómez-Pinedo U, Beas-Zárate C. Proinflammatory cytokines and apoptosis following glutamate-induced excitotoxicity mediated by p38 MAPK in the hippocampus of neonatal rats. J Neuroimmunol 2005; 165:53-62.
13	Ipaktchi K, Mattar A, Niederbichler AD, Hoesel LM, Hemmila MR, Su GL, et al. Topical p38MAPK inhibition reduces dermal inflammation and epithelial apoptosis in burn wounds. Shock 2006; 26:201-209. pmid: 16878030
14	Dreixler JC, Barone FC, Shaikh AR, Du E, Roth S. Mitogen-activated protein kinase p38alpha and retinal ischemic preconditioning. Exp Eye Res 2009; 89:782-790. doi: 10.1016/j.exer.2009.07.006 pmid: 19631642
15	Ou ME, Tang LW, Li H. Effect and signal transduction mechanism of active components of Buyang Huanwu Decoction on vascular adhesion molecule expression. Zhongguo Zhong Xi Yi Jie He Za Zhi 2009; 29:430-434. pmid: 19673335
16	Léveillé F, Papadia S, Fricker M, Bell KF, Soriano FX, Martel MA, et al. Suppression of the intrinsic apoptosis pathway by synaptic activity. J Neurosci 2010; 30:2623-235. doi: 10.1523/JNEUROSCI.5115-09.2010 pmid: 20164347
17	Wang NF, Xu J, Xia Q, Gao Q, Shi XX, Zhou ZL, et al. Mechanism of cardioprotection induced by noninvasive limb ischemic preconditioning. Zhonghua Yi Xue Za Zhi 2009; 89:1999-2002. pmid: 19950578
18	Rácz B, Gallyas F Jr, Kiss P, Tamás A, Lubics A, Lengvári I, et al. Effects of pituitary adenylate cyclase activating polypeptide (PACAP) on the PKA-Bad-14-3-3 signaling pathway in glutamate-induced retinal injury in neonatal rats. Neurotox Res 2007; 12:95-104. pmid: 17967733
19	Lee EJ, Park HG, Kang HS. Sodium salicylate induces apoptosis in HCT116 colorectal cancer cells through activation of p38MAPK. Int J Oncol 2003; 23:503-508. pmid: 12851702

Groups	Number	1 h	6 h	24 h	48 h	72 h
Control group	20	0.40±0.14	0.41±0.15	0.43±0.16	0.40±0.13	0.40±0.14
Model group	20	1.85±0.86^*	4.40±1.26^*	6.70±1.87^*	5.67±1.58^*	0.54±0.19
Low-dose edaravone group	20	1.66±0.80^*	2.46±0.92^*Δ	4.50±1.34^*Δ	2.98±1.02^*Δ	0.49±0.17
High-dose edaravone group	20	1.35±0.76^*	1.17±0.45^*Δ#	2.56±0.98^{*Δ #}	1.87±0.78^*Δ#	0.44±0.16

Groups	Number	1 h	6 h	24 h	48 h	72 h
Control group	20	0.40±0.17	0.52±0.15	0.48±0.12	0.64±0.18	0.44±0.18
Model group	20	0.59±0.29	2.60±1.09^*	4.68±1.56^*	5.34±2.12^*	7.78±3.41^*
Low-dose edaravone group	20	0.56±0.27	1.96±0.82^*Δ	2.49±0.96^*Δ	3.58±1.02^*Δ	5.84±2.17^*Δ
High-dose edaravone group	20	0.60±0.30	1.47±0.51^*Δ#	1.76±0.68^*Δ#	2.22±0.98^*Δ#	3.49±1.19^*Δ#

Groups	Number	Latency for seeking the platform				Times for crossing the original platform
Groups	Number	3d	4d	5d	6d	7d
Control group	5	55.5±7.5	32.7±6.3	25.8±6.5	24.8±5.5	8.20±1.52
Model group	5	120.8±28.0^*	105.6±24.5^*	98.5±21.8^*	92.0±19.5^*	2.28±1.11^*
Low-dose edaravone group	5	84.8±22.8^*Δ	65.20±19.0^*Δ	62.0±16.7^*Δ	59.5±15.6^*Δ	4.17±1.15^*Δ
High-dose edaravone group	5	70.5±20.7^*Δ	55.4±18.49^*Δ	39.0±11.3^*Δ#	32.2±11.0^*Δ#	6.48±1.32^*Δ#

[1]	Jian Lu, Yi Shen, Hui-yin Qian, Li-jun Liu, Bao-chun Zhou, Yan Xiao, Jin-ning Mao, Guo-yin An, Ming-zhong Rui, Tao Wang, Chang-lai Zhu. Effects of mild hypothermia on the ROS and expression of caspase-3 mRNA and LC3 of hippocampus nerve cells in rats after cardiopulmonary resuscitation [J]. World Journal of Emergency Medicine, 2014, 5(4): 298-305.
[2]	Qiang Su, Lang Li, Yang-chun Liu, You Zhou, Wei-ming Wen. Effect of metoprolol on myocardial apoptosis after coronary microembolization in rats [J]. World Journal of Emergency Medicine, 2013, 4(2): 138-143.
[3]	Zhi-jian Zhang, Li-bo Peng, Ya-juan Luo, Cong-yang Zhou. Prospective experimental studies on the renal protective effect of ulinastatin after paraquat poisoning [J]. World Journal of Emergency Medicine, 2012, 3(4): 299-304.
[4]	Zhi-qiang Cheng, Ji-yuan Han, Peng Sun, Yu-ying Weng, Jiao Chen, Guo-yan Wu, Hong-xia Ma. Edaravone attenuates paraquat-induced lung injury by inhibiting oxidative stress in human type II alveolar epithelial cells [J]. World Journal of Emergency Medicine, 2012, 3(1): 55-59.